Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.

Pelletier M, Yang J, Joshi M, Grauel A, Abecunas C, Altzerinakou MA, Zhou Z, Zhu X, Clark K, Li L, Bai LY, Milella M, Mercade TM, Tai WMD, Bockorny B, Grell P, Sivakumar S, Wong MK, Chee CE, Aparicio T, Prager G, Bostel G, Schiessl B, Maacke H, Dranoff G, Shaw A, Fabre C, Mataraza J, Malek S, Cremasco V

Open source

DOI: 10.1158/1078-0432.ccr-26-0805
Published: 2026 Sep 15
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-26-0805,
  title = {Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.},
  author = {Pelletier M and Yang J and Joshi M and Grauel A and Abecunas C and Altzerinakou MA and Zhou Z and Zhu X and Clark K and Li L and Bai LY and Milella M and Mercade TM and Tai WMD and Bockorny B and Grell P and Sivakumar S and Wong MK and Chee CE and Aparicio T and Prager G and Bostel G and Schiessl B and Maacke H and Dranoff G and Shaw A and Fabre C and Mataraza J and Malek S and Cremasco V},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-26-0805},
  url = {https://doi.org/10.1158/1078-0432.ccr-26-0805}
}

RIS

TY  - JOUR
TI  - Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.
AU  - Pelletier M
AU  - Yang J
AU  - Joshi M
AU  - Grauel A
AU  - Abecunas C
AU  - Altzerinakou MA
AU  - Zhou Z
AU  - Zhu X
AU  - Clark K
AU  - Li L
AU  - Bai LY
AU  - Milella M
AU  - Mercade TM
AU  - Tai WMD
AU  - Bockorny B
AU  - Grell P
AU  - Sivakumar S
AU  - Wong MK
AU  - Chee CE
AU  - Aparicio T
AU  - Prager G
AU  - Bostel G
AU  - Schiessl B
AU  - Maacke H
AU  - Dranoff G
AU  - Shaw A
AU  - Fabre C
AU  - Mataraza J
AU  - Malek S
AU  - Cremasco V
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-26-0805
UR  - https://doi.org/10.1158/1078-0432.ccr-26-0805
ER  -

APA

M, P., J, Y., M, J., A, G., C, A., MA, A., Z, Z., X, Z., K, C., L, L., LY, B., M, M., TM, M., WMD, T., B, B., P, G., S, S., MK, W., CE, C., T, A., G, P., G, B., B, S., H, M., G, D., A, S., C, F., J, M., S, M., & V, C. (2026). Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Phase II, Open-Label, Randomized Study.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-26-0805

Source records

pubmed · retrieved 2026-09-26T21:07:28.090Z